When: Pullback to $260-$264 with 50 SMA holding and volume ≥6M

Then: Deploy 50% of target new capital (Tier 1 add)

When: Pullback to $238-$252 zone with positive momentum divergence

Then: Deep re-engagement (Tier 3 add)

When: Q3 earnings beat with ex-STELARA bridge ≥9% and constructive FY guide

Then: Upgrade to Overweight

REDUCE position size to 2-3% core weight with 4% hard cap; do not initiate or add at current levels; implement tighter stop-loss framework with soft trigger at $269 and macro circuit breaker at 5.0% 10-year yield.

• Forward P/E of 22.3x implies 41% earnings growth ($8.61 TTM EPS to $12.14 forward estimate) versus actual Q2 revenue growth of 6.6% and flat year-over-year EPS
• MACD histogram swing of 105 basis points (from plus 4.66 on September 4 to minus 0.26) represents a momentum regime change, not a cooldown
• Current risk-reward is poor: approximately 4% upside to 52-week high at $281 versus approximately 12% downside to 200 SMA, a -3 to 1 ratio
• Apollo's $20 billion interest in DePuy Synthes is not a concluded deal; M&A at this scale typically takes 6 to 18 months and carries meaningful non-closure risk
• The 60% rally from May 2025 lows has already priced in the quality rotation; next marginal move in 10-year above 5% would be a multiple compression event, not continued rotation
• Prediction market shows no-cuts at 96% and recession odds at 10%, a combination that historically does not favor defensive dividend payers
• Pipeline catalysts (Tremfya, RYBREVANT, Spravato, Caplyta) are steady-state positives already substantially reflected in the $653 billion market cap and elevated multiple
• Position sizing should be reduced to 2-3% core weight with no additions above 4% until clean breakout above $276 on volume or pullback to $252-$260 zone
• Stop-loss framework: close below $264 triggers 50% trim; add soft re-evaluation trigger at close below $269 (10 EMA) for 25% reduction
• Macro circuit breaker: weekly close of 10-year Treasury above 5.0% triggers 50% trim regardless of price action, invalidating the rotation thesis

→ vs aggressive: Valuation reframe: 22.3x forward P/E implies 41% earnings growth, a skyscraper bar versus actual 6.6% revenue growth; PEG of 2.84 is a red flag regardless of comp set

→ vs aggressive: MACD dismissal: 105 basis point histogram swing is a momentum regime change, not coiled-spring energy; reward-to-risk on adding at $271 with stop at $264 is approximately 1 to 1

→ vs aggressive: HOLD framing: HOLD is a passive continuation of prior decision, not an aggressive bet; unrealized gains are not a license to take on new risk

→ vs aggressive: DePuy catalyst: treating $20 billion interest as near-term re-rating is speculative; base case without deal is a defensive compounder at stretched multiple with negative MACD sell signal, warranting TRIM not HOLD

→ vs aggressive: Macro rotation: the quality rotation has been priced in via 60% rally; break above 5% in 10-year would be multiple compression, not continuation of rotation

→ vs aggressive: Pipeline catalysts: sell-side coverage of JNJ is exhaustive and well-distributed; marginal sell-side upgrade has likely already been made

HOLD at 3-5% sizing with 264 stop and 269 soft trigger; no new capital at current levels; increase to 6% ceiling requires either 276 breakout on volume or 252-260 pullback

• Forward P/E of 22x implies 41% expected earnings growth vs 6.5% revenue growth and roughly flat EPS year-over-year—a significant disconnect
• Position sizing of 3-5% reflects defensive core holding with 0.235 beta and 60-year dividend Aristocrat status; below 3% unnecessarily compresses long-term compounding
• 264 stop confirmed as written; 25% trim soft trigger added at 269 on daily close below 10 EMA
• Conservative's four-to-one downside is exaggerated; actual risk under the existing plan is closer to one-to-one given the 50% trim at 264 and full exit below 252
• DePuy catalyst is real but overstated by aggressive analyst; $20 billion Apollo discussions for $9 billion revenue unit are not a closed deal with confirmed timeline
• Conservative's 5% ten-year yield circuit breaker rejected as mechanical trigger that will fire on flight-to-quality moves that actually benefit JNJ relative to risk assets
• Aggressive's 'HOLD is aggressive' framing is rhetoric, not analysis; it only works if entry was at 264 or 271, not for new capital entering today
• Increase to 6% ceiling conditioned on either confirmed breakout above 276 on volume or pullback into 252-260 zone
• Stock trading within 3% of 52-week high embeds catalyst optionality, making the base case probability of DePuy deal closing at re-rating-supporting multiple lower than aggressive implies
• Conservative's 2-3% sizing is too defensive for a name that can absorb a recession without distress

→ vs aggressive: HOLD is not automatically the highest-upside-capture stance; the 'aggressive' framing only works with favorable cost basis, not for new capital at current levels

→ vs aggressive: DePuy catalyst overstated; $20 billion Apollo discussions for $9 billion unit are not a closed deal, have no confirmed timeline, and large pharma carve-outs have meaningful failure rate

→ vs conservative: Four-to-one downside framing is mathematically exaggerated; measuring from 271 to 200 SMA at 238 ignores the 50% trim at 264 and full exit below 252, making actual risk closer to one-to-one

→ vs conservative: 5% ten-year yield circuit breaker will whipsaw the position and create forced-sale-at-the-bottom dynamic; pre-committing to trim on yield spike is wrong when yields spike on flight-to-quality moves that benefit JNJ

→ vs conservative: 2-3% sizing is too conservative for a 0.235 beta, 60-year dividend Aristocrat with balance sheet that can absorb a recession without distress; sizing for worst case in base case compresses long-term compounding unnecessarily